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Abstract
Background CD133 is one of the most important stem
cell markers in solid cancers. Some recent reports have
described a possible relationship between CD133 and
hypoxia-inducing factor-1-alpha (HIF-1a). The aim of this
study was to clarify the clinical role of CD133 expression
in gastric cancer and to investigate the correlation between
CD133 expression and HIF-1a expression.
Methods We studied 189 gastric cancer patients who
underwent gastrectomy at Kurume University Hospital.
CD133 and HIF-1a expression was examined using
immunohistochemical staining. Fifty-six cases were
CD133 positive, and they were divided into two expression
types: luminal expression of the gland and cytoplasmic
expression. We investigated the relationship among CD133
expression types, clinicopathological variables, prognosis,
and HIF-1a expression.
Results When comparing clinicopathological variables,
expression of CD133 in the cytoplasm was related to
metastasis and tumor progression. However, this relation-
ship was not observed with luminal expression of the gland
type. The survival rate in patients with cytoplasmic CD133
expression was significantly worse than that in the CD133-
negative group. This relationship was observed in the
survival rate of the adjuvant chemotherapy group and the
curative resection group. Multivariate analysis revealed
that the expression of CD133 in the cytoplasm was an
independent prognostic factor in gastric cancer. Regarding
the correlation between CD133 expression and HIF-1a
expression, the HIF-1a positive rate was lower in patients
with CD133 luminal expression of the gland type and
higher in patients with cytoplasmic expression of CD133.
Conclusion Gastric cancer cells with CD133 expression
in the cytoplasm were cells with high potential for malig-
nancy, and this phenotype was associated with cancer
progression, chemotherapy resistance, recurrence, and poor
prognosis. Cytoplasmic expression of CD133 may be a
useful prognostic marker in gastric cancer. Significant
correlation was observed between HIF-1a expression and
the immunohistochemical staining pattern of CD133.
Keywords Gastric cancer  CD133  Prognosis  HIF-1a
Introduction
Since cancer stem cells (CSCs) in solid cancers [1, 2] were
first reported in the early half of the 2000s, the establish-
ment of a treatment targeting CSCs for radical cure of
cancer has become an important goal. Therefore, the search
for markers to isolate CSCs and characterize cells isolated
with these markers has been active throughout the world.
CD133 is a 120-kDa glycoprotein with five transmem-
brane domains and is a CSC marker. Despite various the-
ories, the biological function of CD133 is still not well
understood. Originally, CD133 was known as a surface
marker of hematopoietic stem cells and progenitor cells,
but CD133 has also recently been reported as a marker of
CSCs in solid cancers such as brain tumors [2], lung cancer
[3], liver cancer [4], colon cancer [5, 6], pancreatic cancer
[7], and prostate cancer [8]. In addition, in lung cancer [9],
breast cancer [10], hepatocellular carcinoma [11], colon
cancer [12], and pancreatic cancer [13], CD133 expression
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has been reported to be strongly related not only to tumor
progression, but also to treatment resistance.
However, despite the large number of patients with
gastric cancer in Japan, CSCs in gastric cancer have not
been definitively reported, and few studies evaluating
CD133 expression have been reported. In highly advanced
gastric cancer and recurrent gastric cancer, compared to
colon cancer, there is still no effective treatment, and
survival rates remain low. Therefore, identification of
gastric CSCs and establishment of treatment will be highly
important in future gastric cancer therapy.
Regarding CSCs, a hypoxic environment has recently
been shown to be necessary to maintain CSCs [14].
Hypoxia-inducing factor-1alpha (HIF-1a) is a downstream
molecule in the mammalian target of rapamycin signaling
pathway, is induced by hypoxemia, and acts as a tran-
scription factor. HIF-1a has attracted attention as a factor
that regulates CD133 expression, and the relationship
between CD133 expression and HIF-1a expression has
been investigated in various solid cancers. Most studies
have shown a correlation between CD133 expression and
HIF-1a expression [15, 16], but interestingly, downregu-
lation of CD133 expression by HIF-1a expression in a
gastric cancer cell line has also been reported [17].
In this study, we investigated the clinicopathological
role of CD133 expression in gastric cancer by immuno-
staining clinical specimens from gastric cancer patients.
We also evaluated the relationship between CD133
expression and prognosis of gastric cancer. In addition, we
examined the relationship between CD133 expression and
HIF-1a expression using immunohistological staining of
gastric cancer tissue specimens.
Materials and methods
Patients
Paraffin specimens from 189 gastric cancer patients who
underwent gastrectomy between January 2004 and August
2006 at Kurume University Hospital were selected. Double
cancer, multiple cancer, mucosal cancer, postendoscopic
mucosal resection, and endoscopic submucosal dissection
cases were excluded from this study. Histopathological
characteristics and each classification are defined in the
Japan Classification of Gastric Carcinoma (14th edition)
[18]. The patient characteristics are shown in Table 1.
Mean age was 66 years, and there were more men than
women. Regarding histological type, we divided the
patients into a differentiated group (tub1, tub2, pap), and an
undifferentiated group (por1, por2, sig, muc). The residual
tumor (R) was defined as R0, no residual tumor; R1,
microscopic residual tumor (positive resection margin or
CY1); or R2, macroscopic residual tumor. None of the
patients had received preoperative adjuvant therapy, but 82
patients had received postoperative adjuvant therapy.
This study was authorized in advance by the Ethics
Committee of Kurume University (study number 11040).
CD133 staining
CD133 expression and HIF-1a expression were examined
with immunohistochemical staining. Surgical specimens
were fixed in 10 % formaldehyde, embedded in paraffin,
and cut into 4-lm-thick sections. We chose the most
invasive section from the gastric cancer tumor. Sections
were deparaffinized in xylene and rehydrated in a graded
series of ethanol. Slides were heated at 120 C in an
autoclave in 10 mM sodium citrate (pH 6.0) for 10 min and
then cooled to room temperature. After blocking with 10 %
horse serum, the sections were incubated overnight at 4 C
with mouse monoclonal anti-CD133 antibody [Milteny
Biotec, Auburn, CA, USA; diluted 1:100 in phosphate-
buffered saline (PBS)]. After washing, sections were
overlaid with secondary antibody (VECTASTAIN elite
Table 1 Patient information
Characteristic Number of patients
(n = 189)
Age (mean ± SD), years 66 ± 11
Gender (male/female) 133/56
Tumor size (mean ± SD), mm 66 ± 38
Histological typea (differentiated/
undifferentiated)
81/108
Stage (I/II/III/IV) 62/41/52/36
Surgery
Total gastrectomy (include remnant
gastrectomy)
72
Distal gastrectomy 99
Proximal gastrectomy 11
Segmental gastrectomy 7
R (residual tumor)b, 0/1/2 144/11/34
Adjuvant chemotherapy (-/+) 107/82
Regimen
TS-1c 37
Oral anticancer drug except TS-1 25
TS-1 + continuous infusion anticancer
drug
15
Details unknown 5
SD standard deviation
a Differentiated (tub1, tub2, pap); undifferentiated (por1, por2, sig,
muc)
b R0, nonresidual tumor; R1, microscopic residual tumor (positive
resection margin or CY1); R2, macroscopic residual tumor
c TS-1 is an oral anticancer drug containing a 5-fluorouracil deriva-
tive (tegafur)
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ABC kit Universal; Vector Laboratories, Burlingame, CA,
USA) for 30 min at room temperature. Sections were
incubated in 3.0 % hydrogen peroxide in PBS for 30 min
to block endogenous peroxidase activity. The reaction was
developed using avidin–biotin–peroxidase complex. The
peroxidase reaction was developed with 3-amino-9-eth-
ylcarbazole, and sections were counterstained with hema-
toxylin. Colon cancer sections were used as a positive
control. Negative control sections (isotype control) were
incubated with normal mouse serum instead of the primary
antibody.
HIF-1a staining
Isobe et al. [19] have reported detailed methods for
immunohistochemical staining of HIF-1a. Briefly, 4-lm-
thick sections were cut from archival formalin-fixed par-
affin-embedded tissue blocks. Slides were irradiated at
99 C in a microwave oven for 30 min in 10 mM citrate
buffer (pH 9.0) and cooled to room temperature. The sec-
tions were incubated overnight at 4 C with rabbit poly-
clonal anti-HIF-1a antibody H206 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA; diluted 1:100 in
PBS), and reactions were developed using the same method
as CD133 staining.
Double immunohistochemical staining
To clarify the localization of CD133 in gastric cancer cells,
double immunohistochemical staining with anti-CD133
antibody and anti-cytokeratin 8 antibody was performed in
some cases. The reaction was developed using anti-mouse
poly-alkaline phosphatase (AP) and anti-rabbit poly-
horseradish peroxidase (HRP) polymerization technology.
We used a cocktail of primary antibodies containing the
same anti-CD133 antibody (diluted 1:100 in PBS) and
rabbit monoclonal anti-cytokeratin 8 antibody (Abcam,
Cambridge, UK; diluted 1:50 in PBS). After incubating
overnight at 4 C, sections were overlaid with secondary
antibody (MACH2 Double Stain 1 Mouse-AP ± Rabbit-
HRP; Biocare Medical, Concord, CA, USA). The alkaline
phosphatase reaction for the anti-CD133 antibody was
developed with Vulcan fast red chromogen (Biocare
Medical; Vulcan Fast Red Chromogen Kit2), and the per-
oxidase reaction for the cytokeratin 8 antibody was
developed with 3,30-diaminobenzidine (DAB).
In addition, to confirm both CD133 and HIF-1a
expression in gastric cancer, double immunohistochemical
staining was performed in some cases. The reaction was
developed using AP and HRP polymerization technology
as described above. We used a cocktail of primary anti-
bodies containing the same anti-CD133 antibody (diluted
1:100 in PBS) and the same anti-HIF-1a antibody (diluted
1:100 in PBS). The secondary antibody and the alkaline
phosphatase reaction were developed using the same
methods as described for the CD133 ? cytokeratin 8
staining. The peroxidase reaction for the anti-HIF-1a
antibody was developed with DAB.
Statistical analysis
For comparison of categorical data, the chi-square test and
Fisher’s exact test were used. The overall survival rate was
calculated using Kaplan–Meier analysis, and differences
between the groups were compared using the log-rank test.
For multivariate analysis, prognostic factors were analyzed
using Cox’s proportional hazard model. All statistical
analysis was performed using statistical software (JMP 9.0;
SAS, Cary, NC, USA). P \ 0.05 was considered statisti-
cally significant.
Results
Immunohistochemical findings
Positive expression for CD133 was observed only in cancer
cells. Two general expression types were observed in
gastric cancer (Fig. 1a, b). In differentiated gastric cancer
in particular, we observed luminal expression of the gland
(defined as L-type) as in colon cancer [20], and in undif-
ferentiated gastric cancer in particular, we saw expression
in the cytoplasm (defined as C-type) as in pancreatic cancer
[21]. In some cases, we saw both L-type and C-type on the
same section. We defined the more dominant expression
type as the main type in the specimens. CD133 expression
was evaluated in 1,000 cancer cells in high-power fields.
The frequency of CD133 expression cells in 1,000 cancer
cells was 0–18.3 %. In 6 cases, we stained some sections
from the gastric cancer tumor, but there were no differ-
ences in the CD133 expression frequency and expression
type (data not shown). CD133 expression was observed in
128 of 189 cases (67.7 %). We defined CD133 positive as
more than 5 % positively stained cancer cells. Of the 189
total cases, we observed 56 CD133-positive cases
(29.6 %), 33 L-type cases (17.4 %), and 23 C-type cases
(12.1 %).
HIF-1a expression was observed in the nucleus of
cancer cells (Fig. 2). Concomitant cytoplasmic staining
was ignored because HIF-1a protein is functionally active
in the nucleus. We defined HIF-1a as positive when more
than 5 % of cancer cells showed positive nuclear expres-
sion. Of the 189 total cases, 107 (56.6 %) were HIF-1a
positive.
Cytokeratin 8 is a cytoplasmic marker of adenocarcinoma
including gastric cancer. Double immunohistochemical
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staining with anti-CD133 antibody and anti-cytokeratin 8
antibody revealed that cytoplasmic expression of CD133
was present mainly in the intracytoplasmic lumen (ICL)
(Fig. 3). The occurrence of ICL, which is well known in
breast cancer, has been reported in gastric cancer [22].
Gastric cancer specimens were confirmed to express
both CD133 and HIF-1a. Moreover, HIF-1a expression in
the nucleus tended to be present more often in C-type than
L-type cases (Fig. 4).
Clinicopathological significance of CD133 expression
First, we investigated the clinicopathological role of CD133
expression in gastric cancer. Table 2 shows the relationship
between expression of CD133 and clinical variables. We
divided our cases into three groups: CD133 negative, L-type
positive, and C-type positive. The rates of lymph node
metastasis, peritoneal dissemination, vascular invasion, and
advanced stage tended to be higher in the C-type-positive
group than in the other two groups, and significant
Fig. 2 Expression of hypoxia-inducible factor (HIF)-1a was seen in
the nucleus of cancer cells. 9400
Fig. 3 Double immunohistochemical staining with anti-CD133 anti-
body (red) and anti-cytokeratin 8 antibody (brown). In the C-type, CD133
was mainly expressed in the intracytoplasmic lumen (ICL). 9400
Fig. 4 Gastric cancer was confirmed to express both CD133 (red)
and HIF-1a (brown). We observed HIF-1a expression in the nucleus
in the C-type. 9400
Fig. 1 Two general CD133 expression types were observed in gastric cancer. a Luminal expression in the gland (L-type). b Expression in the
cytoplasm (C-type). a, b 9200
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Table 2 Comparison of clinical
variables between CD133-
positive and CD133-negative
cases
Variable CD133 expression
Negative (n = 133) Positive P value
L-type positive (n = 33) C-type positive (n = 23)
Age (years)
\70 74 (56 %) 15 (45 %) 11 (48 %) 0.503
C70 59 (44 %) 18 (54 %) 12 (52 %)
Gender
Male 88 (66 %) 31 (94 %) 14 (61 %) 0.004
Female 45 (33 %) 2 (6 %) 9 (39 %)
Macroscopic type
0 43 (32 %) 9 (27 %) 5 (21 %) 0.176
1, 2 32 (24 %) 13 (39 %) 4 (17 %)
3, 4 58 (43 %) 11 (33 %) 14 (60 %)
Diameter (mm)
\70 73 (55 %) 22 (67 %) 10 (43 %) 0.219
C70 60 (45 %) 11 (33 %) 13 (56 %)
Region
U 33 (25 %) 12 (36 %) 7 (30 %) 0.230
M 37 (27 %) 3 (9 %) 6 (26 %)
L 63 (47 %) 18 (54 %) 10 (43 %)
T classification
1, 2 59 (44 %) 12 (36 %) 7 (30 %) 0.374
3, 4 74 (55 %) 21 (63 %) 16 (69 %)
N classification
0 71 (53 %) 16 (48 %) 4 (17 %) 0.006
1, 2, 3 62 (46 %) 17 (51 %) 19 (82 %)
Lymph node metastasis number
0 71 (53 %) 16 (48 %) 4 (17 %) 0.011
1–6 23 (17 %) 10 (30 %) 7 (30 %)
C7 39 (29 %) 7 (21 %) 12 (52 %)
M classification
0 114 (86 %) 27 (82 %) 13 (57 %) 0.003
1 19 (14 %) 6 (18 %) 10 (43 %)
H classification
0 132 (99 %) 29 (87 %) 20 (87 %) 0.001*
1 1 (1 %) 4 (12 %) 3 (13 %)
P classification
0 121 (91 %) 32 (97 %) 16 (70 %) 0.024*
1 12 (9 %) 1 (3 %) 7 (30 %)
CY classification
0 124 (93 %) 32 (97 %) 20 (87 %) 0.521*
1 9 (7 %) 1 (3 %) 3 (13 %)
Stage
I, II 80 (60 %) 17 (52 %) 6 (26 %) 0.009
III, IV 53 (39 %) 16 (48 %) 17 (73 %)
Histological typea
Differentiated 51 (38 %) 25 (75 %) 5 (22 %) \0.001
Undifferentiated 82 (61 %) 8 (24 %) 18 (78 %)
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differences among these three groups were observed. No
correlation was observed in the L-type-positive group.
Thus, we hypothesized that CD133 expression in the cyto-
plasm was related to cancer progression.
Prognostic significance of CD133 expression
Figure 5 shows the relationship between prognosis and
CD133 expression. The overall survival rate for the
a b
c d
Fig. 5 Kaplan–Meier survival curves of 189 patients with gastric
cancer, stratified by CD133 expression. a The 5-year overall survival
(OS) rate of the CD133-negative (-) group was 66.6 %; for the
positive (?) group, OS was 46.3 % (P = 0.004 with the log-rank
test). b Divided into two expression types, the 5-year OS rate of the
L-type (?) was 62.5 %; for the C-type (?), the OS was 22.7 %.
P = 0.603 between CD133 (-) and L-type (?), and P \ 0.001
between CD133 (-) and C-type (?). c Survival curves of stage I/II.
The 5-year OS rate of C-type (?) was 60.0 %. There was no
significant difference in the survival curves between CD133 (-) and
C-type (?) (P = 0.191). d In stage III/IV, the 5-year survival rate of
C-type (?) was 11.7 %. There was a significant difference in the
survival curves between CD133 (-) and C-type (?) (P = 0.017)
Table 2 continued
Histopathological
characteristics and each
classification are defined
according to the Japan
Classification of Gastric
Carcinoma (14th edition)
L-type luminal expression of the
gland type, C-type expression in
the cytoplasm type
a Differentiated (tub1, tub2,
pap); Undifferentiated (por1,
por2, sig, muc)
* Calculated with Fisher’s exact
test
Variable CD133 expression
Negative (n = 133) Positive P value
L-type positive (n = 33) C-type positive (n = 23)
Stroma
med, int 104 (78 %) 31 (94 %) 14 (61 %) 0.011
sci 29 (21 %) 2 (6 %) 9 (39 %)
INF
a, b 83 (62 %) 29 (87 %) 11 (48 %) 0.004
c 50 (37 %) 4 (12 %) 12 (52 %)
ly
0, 1 58 (44 %) 13 (39 %) 4 (17 %) 0.059
2, 3 75 (56 %) 20 (60 %) 19 (82 %)
v
0, 1 125 (94 %) 30 (91 %) 17 (74 %) 0.004*
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CD133-positive group was significantly worse than that in
the CD133-negative group (Fig. 5a). When the CD133-
positive cases were divided into two expression types, the
C-type-positive group showed significantly worse survival
(Fig. 5b). This tendency was present regardless of the stage
(Fig. 5c, d). For prognosis with multivariate analysis, we
controlled for T, N, and P factors, which were strong
prognostic factors selected with backward stepwise
regression, and for pathological type and HIF-1a expres-
sion, which may be confounding factors. Multivariate
analysis revealed that CD133 C-type positive was an
independent prognostic factor in gastric cancer (Table 3).
Relationship between CD133 expression
and chemotherapy resistance and recurrence
Furthermore, we investigated the relationship between
CD133 expression and chemotherapy resistance and
recurrence. We selected patients who underwent adjuvant
chemotherapy and a curative resection, and disease-specific
survival rate curves were compared among the CD133
expression types. In both the adjuvant chemotherapy group
and the curative resection group, the survival rate curve of
the C-type-positive group was significantly worse than that
in the other groups (Figs. 6, 7).
Correlation between CD133 expression and HIF-1a
expression
Finally, we examined the correlation between CD133
expression and HIF-1a expression. There was no signifi-
cant difference in HIF-1a expression between the CD133-
positive and CD133-negative groups. However, when we
analyzed the groups according to expression type, the HIF-
1a-positive rate was lower in L-type and higher in C-type
cases. We found a significant difference in the HIF-1a
expression rate among these three groups (Fig. 8a, b).
We have previously reported that HIF-1a expression is a
poor prognostic factor in gastric cancer [19]. In the present
study, the overall survival rate curve of the HIF-1a-positive
group was significantly worse than that in the HIF-1a-
negative group (Fig. 9a). However, if we divided the HIF-
1a-positive group according to CD133 expression, both the
CD133-positive and the HIF-1a-positive groups showed
poor prognosis. Interestingly, a similar result was seen
without regard to the CD133 expression type (Fig. 9b).
Discussion
We found that CD133 protein expression in gastric cancer
clinical specimens was the same as that in other solid
cancers. CD133 expression was detected in about 30 % of
cases. This expression could be broadly divided into two
types: glandular-luminal cell membrane surface expression
(luminal expression, L-type) and cytoplasmic expression
Table 3 Multivariate analysis of the relationship between CD133
expression type and overall survival
Analysis CD133 expression
Negative L-type positive C-type positive
Univariate
HR 1 1.18 3.62
95 % CI – 0.59–2.18 1.99–6.29
P value – 0.604 \0.001
Multivariate
Model 1a
HR 1 1.16 3.59
95 % CI – 0.57–2.19 1.97–6.24
P value – 0.654 \0.001
Model 2b
HR 1 1.02 1.92
95 % CI – 0.50–1.94 1.02–3.45
P value – 0.945 0.041
Model 3c
HR 1 1.06 1.87
95 % CI – 0.52–2.05 1.00–3.39
P value – 0.846 0.049
We confined the variables that were incorporated into the analysis to
nine from the number of events
HR hazard ratio, CI confidence interval
a Model 1 was analyzed using the Cox proportional hazard model
while controlling for age (\70 years, C70 years) and gender
b Model 2 includes model 1 variables plus T (1, 2/3, 4), N (0/1, 2, 3),
and P (0/1) classifications
c Model 3 includes model 2 variables + HIF-1a expression and his-
tological type (differentiated, undifferentiated)
Fig. 6 Kaplan–Meier survival curves of 82 patients who underwent
adjuvant chemotherapy (adjuvant chemotherapy included all chemo-
therapeutic regimens and durations of administration). P = 0.341
between CD133 (-) and L-type (?); P \ 0.001 between CD133 (-)
and C-type (?)
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(C-type). Luminal expression was more common in dif-
ferentiated gastric cancer, and cytoplasmic expression was
more common in undifferentiated gastric cancer, and both
expression types were seen in some tissue sections. Ishi-
gami et al. [23] and Zhao et al. [24] also evaluated CD133
expression in gastric cancer using clinical specimens, and
both reported two types of staining results, similar to our
findings. Originally, luminal expression of CD133 was
reported in colorectal cancer, and cytoplasmic expression
of CD133 was reported in pancreatic cancer [20, 21].
However, both expression types have recently been
reported at the same time in colon cancer and in hepato-
cellular carcinoma [25, 26].
These reports also support the possibility of two types of
CD133 expression in gastric cancer. A definitive difference
was reported in another article about the expression of
CD133 in gastric cancer [23]. Ishigami et al. [23] evaluated
the overall CD133 expression in gastric cancer, without
dividing the cases into expression types. On the other hand,
in our study, we focused on these two expression types,
with the analysis divided for each expression type. Ishi-
gami et al. [23] reported that CD133 expression in gastric
cancer is a risk factor for tumor progression, prognosis,
depth of invasion, and lymph node metastases. In our
study, the CD133 cytoplasmic expression was certainly
related to tumor progression, primarily metastasis such as
lymph node metastasis, peritoneal dissemination, and vas-
cular invasion. With multivariate analysis, cytoplasmic
CD133 expression was an independent prognostic factor.
However, we did not find a definitive relationship between
luminal CD133 expression and the degree of malignancy.
Sasaki et al. [25] reported that in hepatocellular carci-
noma, cytoplasmic CD133 expression, rather than mem-
branous expression, is related to the degree of malignancy
and prognosis. In rectal cancer as well, cytoplasmic CD133
expression is related to local recurrence and prognosis in a
group that underwent preoperative chemotherapy and
radiotherapy [27]. These reports suggest that cytoplasmic
CD133 expression alone may also be involved in the
degree of malignancy of gastric cancer. It is widely known
that some proteins gain biological function based on their
site of expression. CD133 may be one of these types of
proteins.
What is the significance of CD133 luminal expression?
In an interesting report, Fukamachi et al. [28] used fluo-
rescence-activated cell sorting (FACS) analysis of gastric
cancer tissue and reported that loss of CD133 expression
on the glandular luminal surface may be related to gastric
Fig. 7 Kaplan–Meier survival curves of 144 patients with R0 status
(R0 is a curative resection with negative resection margins).
P = 0.563 between CD133 (-) and L-type (?), and P = 0.013
between CD133 (-) and C-type (?)
a b
Fig. 8 Correlation between CD133 expression and HIF-1a expres-
sion. a HIF-1a expression rate was 59.4 % in the CD133-negative
group and 40.6 % in the CD133-positive group. There was no
significant difference between the two groups (P = 0.234). b The
cases were divided into two expression types. The HIF-1a expression
rate was 33.3 % in the L-type-positive group and 73.9 % in the
C-type-positive group. P = 0.041 among the three groups
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tumor progression. However, our study results suggest that
release of CD133 from the cytoplasm of undifferentiated
gastric cancer cells into the glandular lumen may promote
gland duct formation. In any case, CD133 expression likely
plays some role in differentiation, as shown by Yang et al.
[29].
Therefore, are CD133-expressing cancer cells actually
CSCs? Characteristics of CSCs include tumorigenicity,
treatment resistance, and tumor recurrence. Among these,
tumorigenicity would be difficult to demonstrate in this
study. Therefore, we investigated treatment resistance and
tumor recurrence. The survival rate in the postoperative
adjuvant chemotherapy group and the curative resection
group was regarded as an indicator of treatment resistance
and recurrence. Among these patients, the survival rate in
the cytoplasmic CD133 expression group was significantly
lower than in the other groups. This finding showed that the
cytoplasmic CD133 expression group acquired treatment
resistance and was more likely related to tumor recurrence.
In summary, cancer cells with cytoplasmic CD133
expression were related to tumor progression (primarily
metastases) and prognosis, and were associated with more
undifferentiated tumors, treatment resistance, and more
likely recurrence. These results suggested that these cells
may have CSC-like characteristics.
Finally, regarding the relationship between CD133
expression and HIF-1a expression, in the luminal CD133
expression group in our study, the HIF-1a expression rate
was lower, similar to that which was reported by Matumoto
et al. [17]. However, in the cytoplasmic CD133 expression
group, the HIF-1a expression rate was higher, similar to
that reported for other organs. This finding suggests that for
cytoplasmic CD133 expression with a high degree of
malignancy, HIF-1a may upregulate its expression. In fact,
in our study as well, the survival rate in gastric cancer in
the HIF-1a expression group was lower. Even among cases
in the HIF-1a expression group, in the group that was also
CD133 positive, the survival rate was even lower. This
result may have been because HIF-1a upregulated the
cytoplasmic CD133 expression. However, in our study,
even when the HIF-1a (?) CD133 (?) poor prognosis
group was further classified based on CD133 expression
type, no differences in survival rate based on expression
type were observed. One possibility is that among the
luminal CD133 expression group, those with HIF-1a
expression also showed cytoplasmic CD133 expression.
Considering the relationship between CD133 and HIF-
1a based on our study results, HIF-1a expression is
increased with hypoxia, CD133 is expressed or retained in
cancer cell cytoplasm, and tumor progression occurs as a
result of this CSC-like function. In addition, release from
this hypoxic state, namely via decreased HIF-1a, promotes
the release of CD133 from the cytoplasm, which may then
function in gland duct formation. If this is the case, then
inhibiting HIF-1a expression may lead to improved prog-
nosis in gastric cancer. However, before reaching this
conclusion, it will be necessary to establish an accurate
method for isolating the CD133 expression types and to
conduct studies in gastric cancer cell lines using these
isolated expression types.
Conclusion
In our present study, gastric cancer with cytoplasmic
CD133 expression was associated with lymph node
metastases, peritoneal dissemination, chemotherapy resis-
tance, recurrence, and poor prognosis. Evaluation of
a b
Fig. 9 Kaplan–Meier survival curves of 189 patients with gastric
cancer, stratified by HIF-1a expression and CD133 expression. a The
5-year OS rate was 70.2 % for the HIF-1a-negative (-) group and
53.2 % for the positive (?) group. P = 0.017 with the log-rank test.
b Stratified by CD133 expression type, the 5-year OS rate of the HIF-
1a (?)/CD133 (-) group was 63.0 %. For the HIF-1a (?)/L-type (?)
group, OS was 27.2 %. For the HIF-1a (?)/C-type (?) group, OS was
25.1 %. P = 0.332 between the HIF-1a (-) and HIF-1a (?)/CD133
(-) groups, P = 0.001 between the HIF-1a (-) and HIF-1a (?)/L-
type groups, and P \ 0.001 between the HIF-1a (-) and HIF-1a (?)/
C-type (?) groups
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cytoplasmic CD133 expression in gastric cancer tissue
sections may be useful in the future as a novel prognostic
factor. Moreover, a significant correlation between HIF-1a
expression and the CD133 immunohistochemical staining
pattern was found.
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